These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: High specific activity [samarium-153] EDTA for imaging of experimental tumor models.
    Author: Tse JW, Wiebe LI, Noujaim AA.
    Journal: J Nucl Med; 1989 Feb; 30(2):202-8. PubMed ID: 2500500.
    Abstract:
    Enriched samarium oxide (98.2% 152Sm2O3) was irradiated in low neutron flux and high neutron flux reactors to produce 153Sm with specific activities of 14.3 GBq and 22.1 TBq mmol-1 Sm, respectively, at the time of use. Formulation of 153Sm as [153Sm]EDTA, with a 1:10 molar ratio of SM:EDTA, provided a stable radiotracer in vitro and in vivo. High specific activity [153Sm]EDTA showed superior uptake in cell culture (20.8 +/- 0.9% vs. 5.5 +/- 0.1% for 6 and 600 pmol Sm per 10(6) cells, respectively) and better tumor index values (51 vs. 37 at 10.9 nmol and 1.09 mumol Sm kg-1, respectively) in the BDF1 mouse/Lewis lung tumor model. High specific activity [153Sm]EDTA scintigrams of Copenhagen x Fisher rats bearing transplanted Dunning R3327 tumors clearly delineated the tumors within 6 hr, with moderate liver and bone uptake and low soft-tissue background. The injected radiotracer underwent rapid central compartment clearance and whole-body elimination. The absence of observed adverse histopathological toxicity combines with high image quality within 6 hr, to support the clinical tumor-imaging potential of this agent. Comparative studies with [67Ga]citrate at molar-equivalent doses indicated that high specific activity [153Sm]EDTA was a superior radiotracer in these in vitro and in vivo models.
    [Abstract] [Full Text] [Related] [New Search]